CFTR and cystic fibrosis: This approach could prove valuable for the screening of patient-specific responses to ORKAMBI® or TRIKAFTA rescue under infection conditions, thus personalizing the combination therapy approaches of CFTR modulators with the appropriate anti-infective (i.e., tobramycin and/or 6K-F17) and improving the efficacy in CF patients.